Simultaneously participating in the US's largest nephrology conference (ASN) and the diabetic foot conference (DFCon) this October
CTO Nadan Lee to personally present AI-based kidney regeneration technology at ASN's 'Innovation Stage'
Leaping forward as an AI hyper-personalized organ regeneration platform company covering everything from skin to kidney regeneration

ROKIT Healthcare (KOSDAQ: 376900, CEO Seokhwan You), an AI hyper-personalized organ regeneration platform company, is accelerating its expansion into the US, the world's largest regenerative medicine market, by participating in major professional conferences in the fields of kidney and diabetic foot in October.

ROKIT Healthcare will present its kidney regeneration technology at the 'American Society of Nephrology (ASN Kidney Week 2026),' the largest academic event in the US nephrology field, and exhibit its AI skin regeneration platform at the 'Diabetic Foot Conference (DFCon 2026)' held in Anaheim, California during the same period.

This is expected to be a crucial turning point, showcasing to US medical professionals that ROKIT Healthcare's regenerative medicine technology is expanding beyond skin tissue to the regeneration of core organs like the kidney.

Kidney Regeneration Technology Takes the Stage at ASN... CTO Nadan Lee to Present

ROKIT Healthcare will attend the ASN with Professor Joseph V. Bonventre and hold a corporate presentation at the ASN Innovation Stage on the 23rd (local time). Chief Technology Officer (CTO) Nadan Lee will take the stage as a speaker to provide an in-depth introduction to the AI hyper-personalized kidney regeneration platform currently under development and the future direction of R&D. Additionally, the company will conduct technology exhibitions and on-site networking through a booth at Innovation Avenue.

Currently, when kidney function is severely damaged, patients face the limitation of relying on dialysis or transplantation. ROKIT Healthcare expects its AI organ regeneration platform—which predicts kidney disease status for five years with a single drop of blood and uses the patient's own tissue and regenerative technology to preserve and regenerate kidney function—to become a vital paradigm in the future of the regenerative medicine field.

Furthermore, the company plans to expand this into a lifecycle AI medical platform that covers 'Predict → Prevent → Regenerate' by integrating AI diagnosis and prediction technologies into the kidney regeneration platform to forecast disease progression, prevent deterioration, and regenerate damaged tissues.

Poster Presentation on Customized Diabetic Foot Regeneration Solution at DFCon 2026

ROKIT Healthcare's US expansion does not stop at the kidney. The company will set up a booth and hold a poster presentation to introduce its platform at 'DFCon 2026,' a specialized event for diabetic foot and limb salvage held from the 22nd to the 24th of this month. Through this, it plans to actively introduce real-world evidence (RWE) of its 'AI hyper-personalized skin regeneration platform'—which differentiates itself from traditional wound care-focused approaches—to US medical professionals and industry stakeholders.

The goal is to go beyond simple product exhibition to explain the value of a regenerative medicine platform applicable in actual clinical settings and to expand its clinical and medical network in the US.

'From Skin to Kidney'... Tackling Intractable Diseases with a Single Platform

The industry is paying close attention to ROKIT Healthcare's simultaneous entry into two representative conferences for intractable diseases, ASN and DFCon. This carries symbolic significance in establishing ROKIT Healthcare in the US market not merely as a bio-company limited to treating a single disease, but as a company possessing a proprietary AI customized regeneration platform expandable to various organs such as the kidney, going beyond skin, diabetic foot ulcers, and cartilage.

It presents a new medical paradigm that departs from the traditional treatment model centered on repetitive drug administration, aiming to fundamentally restore the structure and function of damaged tissues by combining the patient's own tissue with AI, bioprinting, and regenerative engineering.

A representative from ROKIT Healthcare emphasized, "Participating in these US conferences is highly significant as it simultaneously unveils regeneration technologies for two core organs: the diabetic foot and the kidney. We will fully introduce the potential of future medicine—predicting and preventing diseases with AI and regenerating damaged organs tailored to the patient—to the US medical field, using this as a bridgehead for future clinical trials, hospital adoption, and the expansion of our commercialization network."